Inghams Group – FY21 Upgrade

Inghams Group is now under Algo Engine buy conditions following recent signals within the $3.10 to $3.30 price range.

The rally in the share price on Friday was the result of the company upgrading FY21 guidance to EBITDA 203-$213m (statutory $438-448m) and NPAT to be $96-103m.

We have ING trading on a forward yield of 5% and we expect to see mid-single-digit EPS growth over the next 2 – 3 years.

IAG – Update

IAG:ASX is a potential counter-trend recovery trade that’s now on our radar.

6/5 Since writing the above post IAG has continued to move higher.

31/5 Short-term investors may stick with the position as long as the price activity remains above the 10-day average.

Cure ETF – Buy

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

IPL – 1H21 Result

Incitec Pivot is now under Algo Engine buy conditions.

The company reported 1H21 Sales of $1.72m with underlying EBITDA of $286m. The EBIT miss was primarily driven by Fertilizers and Dyno Americas, with Dyno APAC largely in-line.

Our Option Lab AI technology suggests looking at the following call.